A Clinical Study of Molnupiravir to Prevent Severe Illness From Coronavirus Disease 2019 (COVID-19) in People Who Are High Risk (MK-4482-023)

NCT06667700 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

3082

Enrollment

INDUSTRY

Sponsor class

Conditions

Coronavirus Disease (COVID-19)

Interventions

DRUG: Molnupiravir
DRUG: Placebo

Sponsor

Merck Sharp & Dohme LLC